Development of clinically high efficient platforms for individualised treatment of cervix cancer
Not Applicable
- Conditions
- Health Condition 1: C539- Malignant neoplasm of cervix uteri, unspecified
- Registration Number
- CTRI/2021/08/035810
- Lead Sponsor
- Science and Engineering Research Board SERB
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Patients treated within ongoing and completed clinical trials of chemoradiation and brachytherapy for cervix cancer with access to MRI/CT images at the time of diagnosis and brachytherapy.
2. Patients undergoing postoperative or definitive radiotherapy and treated within trials of postoperative or definitive RT.
Exclusion Criteria
1. Lack of disease or toxicity outcomes.
2. Lack of images in the hospital database.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method a) Generation of software for automated target delineation for cervix cancer. <br/ ><br>b) Development and validation of Normal Tissue Complication Plots. <br/ ><br>c) Identify â??high risk patient populationâ?? that may benefit from intensification of treatment in future.Timepoint: 3 Years
- Secondary Outcome Measures
Name Time Method ilTimepoint: Nil